Boehringer Ingelheim’s Obesity Drug Helps Lose Fat Rather Than Muscle, Late-Stage Trial Shows

EXCLUSIVE: Survodutide shows potential to predominantly target visceral fat, its Chief Executive Shashank Deshpande said in an interview.